

**Correction to the article “Viscoelastic Tests in the Evaluation of Haemostatic Disorders in SARS-CoV-2 Infection”, Published on Acta Med Port 2021 Jan;34(1):44-55.**

**Errata ao artigo “Testes Viscoelásticos na Avaliação de Alterações da Hemostase na Infecção por SARS-COV-2”, Publicado em Acta Med Port 2021 Jan;34(1):44-55.**

**On page 45, in the fifth sentence of right-side column, where it reads:** “Direct thrombin inhibitors (DTI) (argatroban, bivalirubin) are used in COVID-19 infected patients with significantly lower antithrombin levels,<sup>24</sup> or if heparin induced thrombocytopenia (HIT) occurs.”

**It should read:** “Direct thrombin inhibitors (DTI) (argatroban, bivalirudin) are used in COVID-19 infected patients with significantly lower antithrombin levels,<sup>24</sup> or if heparin induced thrombocytopenia (HIT) occurs.”

Article published with errors: <https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14784>

**Na página 45, quinto parágrafo da coluna do lado direito, onde se lê:** “Direct thrombin inhibitors (DTI) (argatroban, bivalirubin) are used in COVID-19 infected patients with significantly lower antithrombin levels,<sup>24</sup> or if heparin induced thrombocytopenia (HIT) occurs.”

**Deverá ler-se:** “Direct thrombin inhibitors (DTI) (argatroban, bivalirudin) are used in COVID-19 infected patients with significantly lower antithrombin levels,<sup>24</sup> or if heparin induced thrombocytopenia (HIT) occurs.”

Artigo publicado com erros: <https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/14784>



<https://doi.org/10.20344/amp.15487>